vs
Side-by-side financial comparison of Coherus Oncology, Inc. (CHRS) and GREENE COUNTY BANCORP INC (GCBC). Click either name above to swap in a different company.
GREENE COUNTY BANCORP INC is the larger business by last-quarter revenue ($22.2M vs $12.7M, roughly 1.7× Coherus Oncology, Inc.). GREENE COUNTY BANCORP INC runs the higher net margin — 46.3% vs -295.3%, a 341.6% gap on every dollar of revenue. On growth, Coherus Oncology, Inc. posted the faster year-over-year revenue change (64.9% vs 23.8%). Over the past eight quarters, GREENE COUNTY BANCORP INC's revenue compounded faster (18.9% CAGR vs -47.0%).
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing, manufacturing and commercializing affordable oncology treatments, including FDA-approved biosimilars and novel targeted immuno-oncology therapies. Its core market is North America, serving patients with solid tumors and hematological malignancies to expand access to life-saving cancer care.
Bank of Greene County is an American federally-chartered savings bank headquartered in Catskill, NY. The bank's branches are located in the Upstate New York counties of Greene, Columbia, Albany, Ulster, and Rensselaer.
CHRS vs GCBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $12.7M | $22.2M |
| Net Profit | $-37.6M | $10.3M |
| Gross Margin | 68.3% | — |
| Operating Margin | -359.9% | 52.0% |
| Net Margin | -295.3% | 46.3% |
| Revenue YoY | 64.9% | 23.8% |
| Net Profit YoY | 25.7% | 37.4% |
| EPS (diluted) | $-0.34 | $0.60 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.7M | $22.2M | ||
| Q3 25 | $11.6M | $21.5M | ||
| Q2 25 | $10.3M | $20.5M | ||
| Q1 25 | — | $20.1M | ||
| Q4 24 | — | $17.9M | ||
| Q3 24 | — | $16.9M | ||
| Q2 24 | $10.3M | $16.6M | ||
| Q1 24 | — | $15.7M |
| Q4 25 | $-37.6M | $10.3M | ||
| Q3 25 | $-35.5M | $8.9M | ||
| Q2 25 | $297.8M | $9.3M | ||
| Q1 25 | — | $8.1M | ||
| Q4 24 | — | $7.5M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | $-12.9M | $6.7M | ||
| Q1 24 | — | $5.9M |
| Q4 25 | 68.3% | — | ||
| Q3 25 | 67.8% | — | ||
| Q2 25 | 66.9% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 82.4% | — | ||
| Q1 24 | — | — |
| Q4 25 | -359.9% | 52.0% | ||
| Q3 25 | -383.1% | 47.4% | ||
| Q2 25 | -443.6% | 53.5% | ||
| Q1 25 | — | 44.6% | ||
| Q4 24 | — | 45.0% | ||
| Q3 24 | — | 39.6% | ||
| Q2 24 | -384.9% | 41.2% | ||
| Q1 24 | — | 39.4% |
| Q4 25 | -295.3% | 46.3% | ||
| Q3 25 | -307.1% | 41.2% | ||
| Q2 25 | 2903.9% | 45.6% | ||
| Q1 25 | — | 40.1% | ||
| Q4 24 | — | 41.7% | ||
| Q3 24 | — | 37.1% | ||
| Q2 24 | -125.5% | 40.6% | ||
| Q1 24 | — | 37.3% |
| Q4 25 | $-0.34 | $0.60 | ||
| Q3 25 | $-0.31 | $0.52 | ||
| Q2 25 | $2.57 | $0.55 | ||
| Q1 25 | — | $0.47 | ||
| Q4 24 | — | $0.44 | ||
| Q3 24 | — | $0.37 | ||
| Q2 24 | $-0.11 | $0.39 | ||
| Q1 24 | — | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $172.1M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $61.0M | $258.3M |
| Total Assets | $258.3M | $3.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $172.1M | — | ||
| Q3 25 | $191.7M | — | ||
| Q2 25 | $237.6M | — | ||
| Q1 25 | — | $155.5M | ||
| Q4 24 | — | $166.4M | ||
| Q3 24 | — | — | ||
| Q2 24 | $159.2M | $190.4M | ||
| Q1 24 | — | — |
| Q4 25 | $61.0M | $258.3M | ||
| Q3 25 | $87.8M | $248.2M | ||
| Q2 25 | $119.8M | $238.8M | ||
| Q1 25 | — | $229.0M | ||
| Q4 24 | — | $218.4M | ||
| Q3 24 | — | $216.3M | ||
| Q2 24 | $-84.1M | $206.0M | ||
| Q1 24 | — | $199.2M |
| Q4 25 | $258.3M | $3.1B | ||
| Q3 25 | $516.5M | $3.1B | ||
| Q2 25 | $439.5M | $3.0B | ||
| Q1 25 | — | $3.0B | ||
| Q4 24 | — | $3.0B | ||
| Q3 24 | — | $2.9B | ||
| Q2 24 | $674.9M | $2.8B | ||
| Q1 24 | — | $2.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-19.7M | $6.4M |
| Free Cash FlowOCF − Capex | — | $6.2M |
| FCF MarginFCF / Revenue | — | 28.0% |
| Capex IntensityCapex / Revenue | — | 0.9% |
| Cash ConversionOCF / Net Profit | — | 0.62× |
| TTM Free Cash FlowTrailing 4 quarters | — | $47.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-19.7M | $6.4M | ||
| Q3 25 | $-46.3M | $7.0M | ||
| Q2 25 | $-46.6M | $28.0M | ||
| Q1 25 | — | $7.3M | ||
| Q4 24 | — | $5.3M | ||
| Q3 24 | — | $2.1M | ||
| Q2 24 | $59.7M | $24.9M | ||
| Q1 24 | — | $5.6M |
| Q4 25 | — | $6.2M | ||
| Q3 25 | — | $6.5M | ||
| Q2 25 | — | $27.3M | ||
| Q1 25 | — | $7.3M | ||
| Q4 24 | — | $5.1M | ||
| Q3 24 | — | $2.0M | ||
| Q2 24 | — | $23.4M | ||
| Q1 24 | — | $4.9M |
| Q4 25 | — | 28.0% | ||
| Q3 25 | — | 30.4% | ||
| Q2 25 | — | 133.3% | ||
| Q1 25 | — | 36.1% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 11.8% | ||
| Q2 24 | — | 141.2% | ||
| Q1 24 | — | 31.3% |
| Q4 25 | — | 0.9% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | — | 3.4% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | 9.1% | ||
| Q1 24 | — | 4.2% |
| Q4 25 | — | 0.62× | ||
| Q3 25 | — | 0.78× | ||
| Q2 25 | -0.16× | 3.00× | ||
| Q1 25 | — | 0.91× | ||
| Q4 24 | — | 0.71× | ||
| Q3 24 | — | 0.34× | ||
| Q2 24 | — | 3.70× | ||
| Q1 24 | — | 0.95× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CHRS
| Toripalimab | $12.4M | 97% |
| Other | $388.0K | 3% |
GCBC
Segment breakdown not available.
